港股异动丨药明生物(02269.HK)升超4%再创新高 3月底以来累计涨幅超115%
格隆汇10月12日丨药明生物(02269.HK)急升超4%,高见211.6港元再创历史新高,股价自3月底以来累计涨幅超115%。暂成交1.9亿港元,最新总市值高达2866亿港元。药明生物与专注于肿瘤创新疗法研发及商业化的领导企业德琪医药日前共同宣布,双方正式签署战略合作备忘录,在新药开发和生产方面开展全方位合作,共同推进抗肿瘤创新药物的研发。 管理层曾预计下半年公司将恢复增速,并继续推进产能扩充。招商证券(香港)认为产能扩张的努力和公司领先的生物药CRO技术平台将吸引更多海内外客户并丰富其收入结构。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.